Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Abeona Therapeutics (ABEO) EBIT Margin (2016 - 2025)

Abeona Therapeutics has reported EBIT Margin over the past 13 years, most recently at 422.71% for Q4 2025.

  • Quarterly results put EBIT Margin at 422.71% for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was 1536.91% (changed N/A YoY), and the annual figure for FY2025 was 1536.91%, changed.
  • EBIT Margin for Q4 2025 was 422.71% at Abeona Therapeutics, up from 5698.0% in the prior quarter.
  • Over the last five years, EBIT Margin for ABEO hit a ceiling of 97191.67% in Q4 2021 and a floor of 19023.53% in Q4 2022.
  • Median EBIT Margin over the past 4 years was 362.13% (2025), compared with a mean of 6913.62%.
  • Biggest five-year swings in EBIT Margin: surged 9767433bps in 2021 and later tumbled -11621520bps in 2022.
  • Abeona Therapeutics' EBIT Margin stood at 97191.67% in 2021, then crashed by -120bps to 19023.53% in 2022, then skyrocketed by 98bps to 301.54% in 2023, then tumbled by -40bps to 422.71% in 2025.
  • The last three reported values for EBIT Margin were 422.71% (Q4 2025), 5698.0% (Q2 2025), and 301.54% (Q2 2023) per Business Quant data.